Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.25
(
0.72%
)
Bitcoin
76,792.00
(
-0.80%
)
News Focus
News Focus
Post# of 9090
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jmkobers post# 677

Tuesday, 03/19/2019 1:42:48 PM

Tuesday, March 19, 2019 1:42:48 PM

Post# of 9090
Re: Hugel

The “other” possible entrant that post is referring to is presumably Hugel’s Botulax, which is approved in Korea and Taiwan (http://www.theinvestor.co.kr/view.php?ud=20181204000586 ).

The US development rights to Botulax are owned by a JV of Hugel and an Austrian company called Choma-Pharma (http://www.theinvestor.co.kr/view.php?ud=20181204000586 ); however, it’s unclear whether—or when—this JV might make a serious attempt to bring Botulax to the US market.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote